SUVRETTA CAPITAL MANAGEMENT LLC 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 08:41 am Purchase | 2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | SUVRETTA CAPITAL MANAGEMENT LLC | 255,055 9.990% | 152,215 (+148.01%) | Filing |
| 2021-12-16 4:32 pm Purchase | 2021-12-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE | SUVRETTA CAPITAL MANAGEMENT LLC | 102,840 5.200% | 102,840 (New Position) | Filing |